• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Immix Biopharma, Inc. - Common Stock (NQ: IMMX )

    1.860 +0.110 (+6.29%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Immix Biopharma, Inc. - Common Stock

    < Previous 1 2 3 Next >
    Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2
    From Immix Biopharma, Inc.
    Via GlobeNewswire
    Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board
    From Immix Biopharma, Inc.
    Via GlobeNewswire
    Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2
    From Immix Biopharma, Inc.
    Via GlobeNewswire
    Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201
    From Immix Biopharma, Inc.
    Via GlobeNewswire
    Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum
    From Immix Biopharma, Inc.
    Via GlobeNewswire
    Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma
    From Immix Biopharma, Inc.
    Via GlobeNewswire
    Immix Biopharma on Track to Dose NXC-201 Patients in United States
    From Immix Biopharma, Inc.
    Via GlobeNewswire
    Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial
    From Immix Biopharma, Inc.
    Via GlobeNewswire
    Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative
    Hear from the ~30,000 relapsed or refractory AL Amyloidosis patients in the United States today in their own words 
    From Immix Biopharma, Inc.
    Via GlobeNewswire
    BioMedNewsBreaks — Immix Biopharma Inc. (NASDAQ: IMMX) Closes on $15M Public Offering
    Via Investor Brand Network
    Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock
    From Immix Biopharma, Inc.
    Via GlobeNewswire
    Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis
    From Immix Biopharma, Inc.
    Via GlobeNewswire
    Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock
    From Immix Biopharma, Inc.
    Via GlobeNewswire
    Immix Biopharma Announces Proposed Public Offering of Common Stock
    From Immix Biopharma, Inc.
    Via GlobeNewswire
    Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products
    From Immix Biopharma, Inc.
    Via GlobeNewswire
    Immix Biopharma Announces Dr. Vaishali Sanchorawala, AL Amyloidosis Thought Leader, Director of the Amyloidosis Center at Boston University and Boston Medical Center, Joins Scientific Advisory Board
    Dr. Sanchorawala co-authored landmark study of daratumumab (DARZALEX®) in AL Amyloidosis published in The New England Journal of Medicine, 2021 that led to it becoming a first-line standard of care 
    From Immix Biopharma, Inc.
    Via GlobeNewswire
    Immix Biopharma Announces Dr. Marko Radic, Autoimmune CAR-T Pioneer and Associate Professor at the University of Tennessee Health Science Center, Joins Scientific Advisory Board
    From Immix Biopharma, Inc.
    Via GlobeNewswire
    Immix Biopharma Announces 100% Overall Response Rate (n=10); 23.7 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2023
    From Immix Biopharma, Inc.
    Via GlobeNewswire
    Immix Biopharma to Present at the 2023 JMP Securities Hematology and Oncology Summit
    From Immix Biopharma, Inc.
    Via GlobeNewswire
    Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for Relapsed/Refractory AL Amyloidosis
    Virtual Event to be held on November 29, 2023 at 4:15 p.m. ET 
    From Immix Biopharma, Inc.
    Via GlobeNewswire
    Immix Biopharma Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient Dosing
    From Immix Biopharma, Inc.
    Via GlobeNewswire
    Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 9 Relapsed/Refractory AL Amyloidosis Patients
    From Immix Biopharma, Inc.
    Via GlobeNewswire
    Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 63 Relapsed/Refractory Multiple Myeloma Patients
    From Immix Biopharma, Inc.
    Via GlobeNewswire
    Immix Biopharma Subsidiary Nexcella Announces Dr. Michaela Liedtke, Stanford Medicine Cancer Center Hematology Program Lead and Co-Director Stanford Amyloid Center, Joins Scientific Advisory Board
    From Immix Biopharma, Inc.
    Via GlobeNewswire
    Immix Biopharma Completes 3rd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site
    From Immix Biopharma, Inc.
    Via GlobeNewswire
    Immix Biopharma Inc. (NASDAQ: IMMX) Climbs to New 52-Week High
    Via Investor Brand Network
    Immix Biopharma Announces Complete Response in 9th Relapsed/Refractory AL Amyloidosis Patient in NXC-201 Clinical Trial at IMS 20th Annual Meeting
    From Immix Biopharma, Inc.
    Via GlobeNewswire
    Immix Biopharma Announces 72-Patient NXC-201 Clinical Data at the IMS 20th Annual Meeting, 95% Overall Response Rate in Multiple Myeloma
    From Immix Biopharma, Inc.
    Via GlobeNewswire
    U.S. Food and Drug Administration Approves Orphan Drug Designation for Immix Biopharma NXC-201 as a Treatment for Amyloid Light Chain (AL) Amyloidosis
    From Immix Biopharma, Inc.
    Via GlobeNewswire
    Immix Biopharma Subsidiary Nexcella Completes 2nd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site
    From Immix Biopharma, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.